KEYNOTE-C11: This phase II trial is evaluating how effective a treatment of immunotherapy (pembrolizumab), followed by chemotherapy, and then followed with more immunotherapy is in people with newly diagnosed classical Hodgkin lymphomaPhase 2 Study of Pembrolizumab and Chemotherapy in Patients With Newly Diagnosed Classical Hodgkin Lymphoma (KEYNOTE-C11)

Summary

This is a non-randomised trial with one experimental arm with several phases. All participants will first receive pembrolizumab administered intravenously (via IV) at a dose of 200mg on Day 1 of each 3-week cycle for 3 cycles. All participants will then undergo Positron Emission Tomography (PET) scans, and depending on these results, will receive one of two chemotherapy regimens. Some participants will receive AVD chemotherapy which involves doxorubicin in combination with vinblastine & dacarbazine, and other participants will receive escBEACOPP chemotherapy which involves etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, & prednisone. Following chemotherapy, all participants will receive more pembrolizumab as consolidation therapy. This time, pembrolizumab will be administered via IV at a dose of 400mg on Day 1 of each 6-week cycle for 4 cycles.